Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is a trainee healthcare and pharmaceutical reporter. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Nexsen lays out clinical plans for rapid Strep B test development
Nexsen Biotech plans to evaluate the sensitivity and specificity of its rapid point of care for Group B streptococci (GBS),…
-
Barinthus’ HPV therapy meets primary endpoint in Phase I/II trial
The UK-based Barinthus Biotherapeutics (formerly Vaccitech) has released topline data from its Phase Ib/II APOLLO trial for its human papillomavirus…
-
Hyperfine starts enrolment in portable imaging workflow study
US-based health technology company Hyperfine has enrolled the first patient in the clinical workflow study of its US Food and…
-
Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
-
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
-
Sight Sciences touts eye pressure reduction with glaucoma OMNI device
US-based Sight Sciences has published the two-year post-surgical outcomes of its minimally invasive glaucoma surgery device, the OMNI surgical system.…
-
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
US-based Acarix has initiated a real-world study that compares its AI-powered CADScor System's clinical workflow efficiency with traditional stress tests…
-
OSE wins French govt grant for Phase III trial for cancer vaccine
OSE Immunotherapeutics has received €8.4m ($9m) in non-dilutive funding from the ‘France 2030’ plan funded by the French Government. The…
-
Transgene and NEC’s cancer vaccine shows promise in head and neck cancer
French Biotech Transgene and Japanese NEC Corporation have released follow-up data from the Phase I trial of its individualised cancer…